Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 230Squamous Cell Carcinoma of Head and Neck 139Head and Neck Neoplasms 131Lung Neoplasms 117Esophageal Neoplasms 88Stomach Neoplasms 84Uterine Cervical Neoplasms 68Esophageal Squamous Cell Carcinoma 66Urinary Bladder Neoplasms 59Breast Neoplasms 55Nasopharyngeal Carcinoma 51Small Cell Lung Carcinoma 46Carcinoma, Squamous Cell 39Neoplasm Metastasis 38Pancreatic Neoplasms 36Neoplasms 35Biliary Tract Neoplasms 34Oropharyngeal Neoplasms 32Cholangiocarcinoma 32Ovarian Neoplasms 30Mesothelioma, Malignant 28Adenocarcinoma Of Esophagus 28Lymphoma 25Carcinoma 24Adenocarcinoma of Lung 24Central Nervous System Neoplasms 22Laryngeal Neoplasms 20Carcinoma, Ovarian Epithelial 20Recurrence 19Lymphoma, Large B-Cell, Diffuse 19

Interventions

Fluorouracil 4Oxaliplatin 3Capecitabine 3toripalimab 2dehydroftorafur 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2tremelimumab 1trametinib 1tislelizumab 1temoporfin 1sacituzumab govitecan 1lenvatinib 1gemcitabine-oxaliplatin regimen 1durvalumab 1binimetinib 1Stents 1Sorafenib 1Radiosurgery 1Hydroxychloroquine 1Gemcitabine 1Erlotinib Hydrochloride 1Cisplatin 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Klatskin Tumor × Cisplatin × Clear all
NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡